ARCHIVES

NCI “Can’t Justify Size Of Intramural Program”

This article is from The Cancer Letter archive.

Vol. 21 No. 19 | May 12, 1995

Download PDF Visit The Full Archive

Related Articles

Avastin Improves Survival By 30 Percent In Advanced Non-Small Cell Lung Cancer

June 24, 2005

Harkin to Ask NCI For Accounting Of Antineoplaston Trials

July 2, 1993

Austria Has highest Cancer Rate, Little NCI Support

June 17, 1977

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

July 27, 2012

Novel Agents Promise Relief From Hematologic Side Effects

July 27, 2001

Shubik Group Finally Completes Document On Carcinogenicity Criteria

March 12, 1976